AbbVie, an American pharmaceutical company, agreed to acquire Celsius Therapeutics, a biotechnology company. Financial terms were not disclosed. "AbbVie shares our excitement about the potential of TREM1 inhibition for patients with inflammatory disease. I'd like to thank the Celsius team for their relentless efforts in the discovery of CEL383. We look forward to the further development of this promising program, which we hope will offer a new approach to the treatment of IBD," Tariq Kassum, Celsius Therapeutics CEO.